Chemo with durvalumab before surgery or radiation for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial gives a combination of chemotherapy and durvalumab (an immunotherapy drug) before surgery or radiation, then durvalumab alone afterward. It aims to shrink the tumor and improve outcomes for people with stage III non-small cell lung cancer that is borderline resectable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (NSCLC) that is stage III and considered borderline resectable (meaning surgery might be possible but is risky).
- You have not had any treatment for this cancer yet.
- Your cancer does not have certain gene changes (EGFR or ALK mutations).
- You are generally healthy and able to perform daily activities (ECOG 0 or 1).
- You have adequate organ function (kidney, liver, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This study looks at how the body’s immune system responds in people with stage III lung cancer (not removable by surgery) who first get chemotherapy and radiation and then receive the immunotherapy drug durvalumab for one year. It aims to learn more about the immune response and why the treatment works better for some people.
This trial studies whether adding durvalumab (an immune therapy) to standard chemoradiation before surgery can improve outcomes for people with stage III, resectable lung cancer. It aims to help shrink the tumor and improve chances of successful treatment.
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.